Administer intravaginally using the provided applicator, preferably at bedtime. Fill the applicator to the mark, insert deeply into the vagina, and depress the plunger.

Estriol directly acts on estrogen receptors in the vaginal mucosa, leading to proliferation of vaginal epithelial cells, increased glycogen content, and restoration of the normal acidic vaginal environment. This helps improve vaginal lubrication, elasticity, and reduce symptoms of atrophy.

• •Known, suspected or past breast cancer.
• •Known or suspected estrogen-dependent malignant tumours.
• •Undiagnosed vaginal bleeding.
• •Untreated endometrial hyperplasia.
• •Previous idiopathic or current venous thromboembolism (DVT, PE).
• •Active or recent arterial thromboembolic disease (e.g., angina, myocardial infarction, stroke).
• •Acute liver disease or a history of liver disease where liver function tests have failed to return to normal.
• •Porphyria.
• •Hypersensitivity to the active substance or to any of the excipients.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose is unlikely with intravaginal administration due to minimal systemic absorption. If accidental oral ingestion occurs, symptoms like nausea, vomiting, and vaginal bleeding may appear. Treatment is symptomatic and supportive.

Contraindicated during pregnancy. Not recommended during lactation as estriol is excreted in breast milk and may affect the infant.